文献速递外周动脉疾病

髂动脉疾病初次血管内治疗后再次干预的患者特异性危险因素

Patient-specific risk factors for reintervention following primary endovascular treatment of iliac artery disease.
PubMed 文献 · J Vasc Surg · 2023-12-14

该回顾性队列研究纳入2008年1月至2020年6月在一家三级血管转诊中心连续接受症状性髂动脉疾病血管内血运重建的1113例患者(1538次髂动脉干预),分析患者特异性因素与24个月内临床驱动靶血管血运重建(CD-TVR)的关系。多变量分析显示,年龄增大、肾小球滤过率较高与CD-TVR可能性降低相关,而 common 髂动脉(较外髂动脉)病变与CD-TVR可能性降低相关;传统心血管危险因素与CD-TVR无关联。

要点

  • 年龄增大与CD-TVR可能性降低相关(OR 0.64,95%CI 0.50-0.83,P=.001)。
  • 肾小球滤过率较高与CD-TVR可能性降低相关(OR 0.75,95%CI 0.59-0.95,P=.017)。
  • common 髂动脉(较外髂动脉)病变与CD-TVR可能性降低相关(OR 0.48,95%CI 0.24-0.93,P=.030)。

核心结论

  • 在这项回顾性队列研究中,年龄较轻、肾功能受损和外髂动脉病变与CD-TVR相关。
  • 传统心血管危险因素未见可预测再次干预。

研究设计与样本

  • 回顾性分析2008年1月至2020年6月在一家三级血管转诊中心连续入组的因症状性髂动脉疾病接受血管内血运重建的患者。
  • 共1113例患者(26%女性;68岁)接受1538次髂动脉干预。
  • 主要结局为24个月内CD-TVR发生,次要结局为至CD-TVR时间;24个月内死亡或无需CD-TVR者分别在死亡日期或730天截尾。
  • 主要分析采用多重插补处理缺失数据。

主要发现

  • 108条肢体(74例患者;7.0%)发生CD-TVR,至CD-TVR中位时间为246天。
  • 多变量分析中,年龄增大与CD-TVR可能性降低相关(OR 0.64;95%CI 0.50-0.83;P=.001),并与任意时点CD-TVR风险降低相关(HR 0.66;95%CI 0.52-0.84;P=.001)。
  • 肾小球滤过率较高与CD-TVR可能性降低相关(OR 0.75;95%CI 0.59-0.95;P=.017),并与任意时点CD-TVR风险降低相关(HR 0.73;95%CI 0.58-0.93;P=.009)。
  • common 髂动脉(较外髂动脉)病变血运重建与CD-TVR可能性降低相关(OR 0.48;95%CI 0.24-0.93;P=.030),并与任意时点CD-TVR风险降低相关(HR 0.48;95%CI 0.25-0.92;P=.027)。
  • 传统心血管危险因素(性别、高血压、较高低密度脂蛋白胆固醇、较高糖化血红蛋白、吸烟)与CD-TVR未见关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Predictive models for reintervention may guide clinicians to optimize selection, education, and follow-up of patients undergoing endovascular iliac revascularization. Although the impact of lesion- and device-related characteristics on iliac restenosis and reintervention risk is well-defined, data on patient-specific risk factors are scarce and conflicting. This study aimed to explore the value of patient-related factors in predicting the need for clinically driven target-vessel revascularization (CD-TVR) in patients undergoing primary endovascular treatment of iliac artery disease. METHODS: Consecutively enrolled patients undergoing endovascular revascularization for symptomatic iliac artery disease at a tertiary vascular referral center between January 2008 and June 2020 were retrospectively analyzed. Primary and secondary outcomes were CD-TVR occurrence within 24 months and time to CD-TVR, respectively. Patients who died or did not require CD-TVR within 24 months were censored at the date of death or at 730 days, respectively. Multiple imputation was used to account for missing data in primary analyses. RESULTS: A total of 1538 iliac interventions were performed in 1113 patients (26% females; 68 years). CD-TVR occurred in 108 limbs (74 patients; 7.0%) with a median time to CD-TVR of 246 days. On multivariable analysis, increasing age was associated with lower likelihood of CD-TVR (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.50-0.83; P = .001) and decreased risk of CD-TVR at any given time (hazard ratio [HR], 0.66; 95% CI, 0.52-0.84; P = .001). Similarly, a lower likelihood of CD-TVR (OR, 0.75; 95% CI, 0.59-0.95; P = .017) and decreased risk of CD-TVR at any given time (HR, 0.73; 95% CI, 0.58-0.93; P = .009) were observed with higher glomerular filtration rates. Lastly, revascularization of common vs external iliac artery disease was associated with lower likelihood of CD-TVR (OR, 0.48; 95% CI, 0.24-0.93; P = .030) and decreased risk of CD-TVR at any given time (HR, 0.48; 95% CI, 0.25-0.92; P = .027). No associations were observed between traditional cardiovascular risk factors (sex, hypertension, higher low-density lipoprotein cholesterol, higher hemoglobin A1c, smoking) and CD-TVR. CONCLUSIONS: In this retrospective cohort study, younger age, impaired kidney function, and external iliac artery disease were associated with CD-TVR. Traditional markers of cardiovascular risk were not seen to predict reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Koeckerling D, Zielasek C, Stähli P, et al. Patient-specific risk factors for reintervention following primary endovascular treatment of iliac artery disease. J Vasc Surg. 2023. PMID: 38103806. doi:10.1016/j.jvs.2023.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。